NCT02092818 (EXPERT) is a clinical trial of Riociguat (Adempas, BAY63-2521) in Hypertension, Pulmonary, sponsored by Bayer.

Who is sponsoring NCT02092818?

NCT02092818 is sponsored by Bayer.

What drugs are being tested in NCT02092818?

Interventions in NCT02092818: Riociguat (Adempas, BAY63-2521).

What condition does NCT02092818 study?

NCT02092818 studies Hypertension, Pulmonary.

Is NCT02092818 still recruiting?

NCT02092818 is currently completed. Last updated 19 June 2019.

Last reviewed 2019-06-19 · How we verify

NCT02092818: EXPERT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension

Completed Last updated 19 June 2019

What this trial tests

trial testing Riociguat (Adempas, BAY63-2521) in Hypertension, Pulmonary in 1,316 participants. Completed in 29 June 2018.

Timeline

31 May 2014

Primary endpoint
31 March 2018

29 June 2018

Quick facts

Lead sponsor	Bayer
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,316
Start date	31 May 2014
Primary completion	31 March 2018
Estimated completion	29 June 2018
Sites	28 locations across Italy, Colombia, Finland, Taiwan, Ireland, Denmark, Netherlands, Russia

Drugs / interventions tested

Riociguat (Adempas, BAY63-2521) — full drug profile →

Conditions studied

Hypertension, Pulmonary — all drugs for Hypertension, Pulmonary →

Sponsor

Bayer — full company profile →

Who can join

Eligibility, any sex, with Hypertension, Pulmonary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In accordance with the regulatory guidance this registry has been designed to collect information about the long-term safety of Adempas in real clinical practice outside the regulated environment of a controlled clinical study.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations.
Swinnen K, Quarck R, Godinas L, Belge C, et al · · 2019 · cited 47× · PMID 31852746 · DOI 10.1183/16000617.0050-2019
Riociguat: Clinical research and evolving role in therapy.
Klinger JR, Chakinala MM, Langleben D, Rosenkranz S, et al · · 2021 · cited 27× · PMID 33242341 · DOI 10.1111/bcp.14676
EXPRESS: Switching to riociguat: A potential treatment strategy for the management of CTEPH and PAH.
Benza R, Corris P, Ghofrani A, Kanwar MK, et al · · 2019 · cited 5× · PMID 30803329 · DOI 10.1177/2045894019837849

Verify or expand the search:

Other trials of Riociguat (Adempas, BAY63-2521)

Trials testing the same drug.

NCT04813926 — A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patien · completed
NCT02891850 — Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy · Phase 4 · completed
NCT02562235 — Riociguat in Children With Pulmonary Arterial Hypertension (PAH) · Phase 3 · active not recruiting
NCT02545465 — A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic · completed
NCT02283762 — Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis · Phase 2 · completed

Other recruiting trials for Hypertension, Pulmonary

Currently open trials in the same condition.

NCT07087613 — Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG · recruiting
NCT06814145 — Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023) · Phase 2 · recruiting
NCT05867914 — Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD · NA · active not recruiting
NCT05719415 — Functional Pulmonary Capillary Surface Area in BPA for CTEPH · NA · recruiting
NCT05179876 — A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no O · Phase 3 · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02092818 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 19 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02092818.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing